Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $0.85 per share and revenue of $201.9320 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Pacira BioSciences Trading Up 1.2%

NASDAQ PCRX opened at $23.02 on Thursday. The company has a fifty day moving average of $23.11 and a 200 day moving average of $23.89. The company has a market capitalization of $990.32 million, a PE ratio of 51.16 and a beta of 0.24. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.26 and a quick ratio of 3.78. Pacira BioSciences has a 1 year low of $18.80 and a 1 year high of $27.64.

Insider Activity

In related news, CFO Shawn Cross sold 15,896 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $25.03, for a total transaction of $397,876.88. Following the completion of the transaction, the chief financial officer directly owned 56,250 shares in the company, valued at $1,407,937.50. This trade represents a 22.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Lauren Riker sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total transaction of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 30,416 shares of company stock worth $744,315. 6.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pacira BioSciences

Institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. raised its stake in Pacira BioSciences by 5,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock valued at $39,000 after acquiring an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in Pacira BioSciences in the 4th quarter valued at $48,000. Global Retirement Partners LLC raised its position in Pacira BioSciences by 479.4% during the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock worth $52,000 after buying an additional 1,678 shares during the last quarter. Strs Ohio acquired a new stake in shares of Pacira BioSciences in the 1st quarter worth $75,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Pacira BioSciences in the 3rd quarter worth $80,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Barclays started coverage on Pacira BioSciences in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 price target for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Truist Financial reduced their price objective on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Wall Street Zen upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.75.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.